Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-01-30
2009-06-30
Carlson, Karen Cochrane (Department: 1656)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S320100, C435S252300, C536S023100, C530S350000
Reexamination Certificate
active
07553639
ABSTRACT:
The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 and GRK6 kinases.
REFERENCES:
patent: 6861422 (2005-03-01), Hoffmann et al.
patent: 2004/0176380 (2004-09-01), Hoffmann et al.
patent: 2005/0014761 (2005-01-01), Hoffmann et al.
patent: 2006/0025411 (2006-02-01), Hoffmann et al.
patent: 2006/0057652 (2006-03-01), Green et al.
patent: 2006/0079503 (2006-04-01), Schwede et al.
patent: 2006/0223833 (2006-10-01), Schulze et al.
patent: 2007/0010565 (2007-01-01), Prien et al.
patent: 2007/0010566 (2007-01-01), Prien et al.
patent: 2007/0037862 (2007-02-01), Siemeister et al.
patent: 2007/0135387 (2007-06-01), Michaelides et al.
patent: 2007/0179177 (2007-08-01), Brenchley et al.
patent: 2007/0203143 (2007-08-01), Sheppard et al.
patent: 2008/0160011 (2008-07-01), Chilcote et al.
patent: 2008/0300206 (2008-12-01), Anderson et al.
patent: WO 01/60794 (2001-08-01), None
patent: WO 2004/069175 (2004-08-01), None
patent: WO 2006/073734 (2006-07-01), None
patent: WO 2006/124892 (2006-11-01), None
patent: WO 2007/089862 (2007-08-01), None
Inglis et al. Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in the central nervous system. J. Biol. Chem. Papers in Press, Published Nov. 12, 2008.
Inglis et al., “Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in the central nervous system,” J.Biol. Chem. Papers in Press, pp. 1-11 (2008).
Johnson et al., “Pharmacological and Functional Comparison of the Polo-like Kinase Family: Insight into Inhibitor and Substrate Specificity, Biochemistry,” 46:9551-9563 (2007).
Naoto et al., “Serine 129 phosohorylation of alpha-synuclein induces unfolded protein response-mediated cell death,”Journal of Biological Chemistry, 283(34):23179-23188 (2008), Biosis Previews, Abstract only.
PCT International Preliminary Report on Patentability (Chapter I) of Oct. 28, 2008 with Written Opinion for application PCT/US2007/002685.
PCT Search Report of Sep. 26, 2008 for application PCT/US2007/002685.
Steegmaier et al., “BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth in Vivo,” Current Biology, 17:316-322 (2007).
Winkles et al., “Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues,” Oncogene, 24:260-266 (2005).
Anderson John P.
Banducci Kelly
Basi Guriqbal S.
Chereau David
Chilcote Tami J.
Carlson Karen Cochrane
Elan Pharma International Limited
Townsend and Townsend / and Crew LLP
LandOfFree
Alpha-synuclein kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Alpha-synuclein kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha-synuclein kinase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070335